High frequency of BRAF V600E mutations in ameloblastoma

Journal of Pathology

Volumn 232, Issue 5, 2014, Pages 492-498

  Kurppa, Kari J ^a   Catón, Javier ^b   Morgan, Peter R ^b   Ristimäki, Ari ^c,d   Ruhin, Blandine ^e   Kellokoski, Jari ^f,g   Elenius, Klaus ^a,h   Heikinheimo, Kristiina ^f,h  

^a UNIVERSITY OF TURKU   (Finland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Division of Pathology and Genetics HUSLAB Helsinki University Central Hospital   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

ameloblastoma; BRAF; EGFR; odontogenic tumour; oncogenic mutation; targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; TRASTUZUMAB;

ADOLESCENT; ADULT; AGED; AMELOBLASTOMA; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

AMELOBLASTOMA; BRAF; EGFR; ODONTOGENIC TUMOUR; ONCOGENIC MUTATION; TARGETED THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMELOBLASTOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAW NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895925166     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4317     Document Type: Article

References (25)

1. Gardner DG, Heikinheimo K, Shear M, et al., Pathology and genetics of the head and neck tumours: ameloblastoma. In Word Health Organization Classification of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D, (eds). Lyon: IARC Press, 2005; 296-300.
2. Mendenhall WM, Werning JW, Fernandes R, et al., Ameloblastoma. Am J Clin Oncol 2007; 30: 645-648.
3. Holbro T, Hynes NE,. ErbB receptors: directing key signalling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195-217.
4. Heikinheimo K, Voutilainen R, Happonen RP, et al., EGF receptor and its ligands, EGF and TGFα, in developing and neoplastic human odontogenic tissues. Int J Dev Biol 1993; 37: 387-396.
5. Ueno S, Miyagawa T,. Immunohistochemical investigation of epidermal growth factor receptor expression in ameloblastomas. J Pathol 1994; 173: 33-38.
6. Vered M, Shohat I, Buchner A,. Epidermal growth factor receptor expression in ameloblastoma. Oral Oncol 2003; 39: 138-143.
7. Heikinheimo K, Jee KJ, Niini T, et al., Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res 2002; 81: 525-530.
8. Junttila TT, Laato M, Vahlberg T, et al., Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003; 9: 5346-5357.
9. Capper D, Preusser M, Habel A, et al., Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
10. Harada H, Mitsuyasu T, Nakamura N, et al., Establishment of ameloblastoma cell line, AM-1. J Oral Pathol Med 1998; 27: 207-212.
11. Kibe T, Fuchigami T, Kishida M, et al., A novel ameloblastoma cell line (AM-3) secretes MMP-9 in response to Wnt-3a and induces osteoclastogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115: 780-788.
12. Amado RG, Wolf M, Peeters M, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
13. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
14. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
15. Paez JG, Jänne P, a, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
16. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
17. Lièvre A, Bachet J-B, Le Corre D, et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
18. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al., Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
19. Di Nicolantonio F, Martini M, Molinari F, et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
20. De Roock W, Claes B, Bernasconi D, et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
21. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
22. Hauschild A, Grob JJ, Demidov LV, et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
23. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
24. Cardiff RD, Leder A, Kuo A, et al., Multiple tumour types appear in a transgenic mouse with the ras oncogene. Am J Pathol 1993; 142: 1199-1207.
25. Dodds A, Cannon R, Suggs C, et al., mRNA expression and phenotype of odontogenic tumours in the v-Ha-ras transgenic mouse. Arch Oral Biol 2003; 48: 843-850.